“Angola, no exception to the COVID-19 threat, recognizes the value of REMISSION 1℃”
[Medical Newspaper/Daily News = Reporter Oh In-gyu] “We focused on the initial response and achieved some positive results, but Angola is still facing a serious threat from COVID-19. We need AdipoLABs' products (REMISSION 1°C) and its cutting-edge technology” (Angolan Ambassador to Korea Edgar Gaspar Martins)
AdipoLABs (CEO Han Sung-ho) recently held a donation ceremony for the high-frequency hyperthermia device 'REMISSION 1℃' with Angolan Ambassador to Korea Edgar Gaspard Martins at the AdipoLABs headquarters to provide cancer treatment to the medically underprivileged in Angola, Africa, in order to overcome COVID-19 together..
On this day, Angolan Ambassador to Korea Edgar Gaspard Martins <pictured> met with this newspaper and said, “Angola is a country located in the center of Africa and can help and influence neighboring countries,” adding, “The country is experiencing a lot of healthcare issues, including COVID-19. “I have decided that this is an important technology and I am confident that this new device will create many miracles,” he said.
Angola is located on the South Atlantic coast of western Africa. The large territory, which is about 5.6 times the size of South Korea, is rich in natural resources such as crude oil, diamonds, and iron ore. Colonized by Portugal since the 15th century, the nation became independent in the mid-1970s, and diplomatic relations with Korea were established in 1992.
The average export amount to Angola over the three years from 2018 to 2020 is approximately $160 million. Excluding well-known countries such as South Africa and Nigeria, this amount indicates Angola is not a small export market to Republic of Korea. Many plants and construction-related companies related to Korea's oil development are entering Angola. It is known that Korea has high awareness of used cars, automobile and machinery parts, petrochemical raw materials, and electronic products.
It is said that the reason for requesting cooperation from AdipoLABs despite the market difficulties caused by the economic downturn and the aftermath of COVID-19 was President Joao Lorenzo's strong will.
As another COVID-19
variant named ‘Omicron’, following ‘Delta’, is showing signs of spreading
around the world, mainly in Africa and Europe, the device brings new hope of
cure in the middle of harship.
Key figures, including AdipoLABs CEO Han Sung-ho (third
from the left) and Angolan Ambassador to Korea Edgar Gaspar Martins (fourth
from the left), attended the donation ceremony held at AdipoLABs headquarters.
Remission 1℃ raises our body temperature above 40℃ through high frequency waves, increasing deep heat and resulting in necrosis of heat-vulnerable cancer cells while promoting blood circulation and improving immunity. Based on this, the equipment was certified as a medical device that treats cancer and relieves pain. The device has attracted a great deal of attention of medical officials at major domestic and international exhibitions.
In addition, the role of the International Virus Research Alliance (IVRA), which is increasing its reputation as a collaborative partner for the treatment of COVID-19, in this donation was crucial as well.
At a conference held last September, Professor Jang Hong-seok's team at Seoul St. Mary's Hospital and Seosan Medical Center received acclaim by presenting research results obtained while treating COVID-19 patients using 'Remission 1℃' provided by AdipoLABs.
In this study, two Filipino men were first tested for PCR after two tests over two days, and the results were negative.
Plan for continued cooperation, including conducting
academic seminars where companies are invited to the local area
AdipoLABs, Remission 1℃ product image
As a result of measuring CT values before and after treatment for 20 domestic patients, the average value of the E gene before treatment was 23.66 to 32.63 after treatment. The average value of the RdRP S gene was 24.07 before treatment to 33.18 after treatment. The average value of the N gene before treatment was statistically significant. Results were increasing from 25.22 to 33.24 after treatment.
Ambassador Edgar Gaspard Martins said, “As is well known, the Ebola virus has killed enormous number of people in Africa. Tthe fact that this new medical technology has been tested and applied elsewhere was an important influence on our decision, and both president and I firmly believe that REMISSION 1℃ will be attempted and utilized at all possible places."
He added, “It is important to develop great relationship and our goal is to create opportunities,” adding, “We will continue to cooperate by inviting companies to conduct academic seminars in the future.”
On this day, AdipoLABs CEO Han Sung-ho also said, “Despite the internal and external economic difficulties caused by the COVID-19 pandemic, REMISSION 1℃ has improved the health of many patients.” He added, “In particular, hyperthermia increases immunity and is meaningful in treating the COVID-19 virus. We obtained many positive results. This donation can served as an opportunity to prove the effectiveness of immunotherapy for many patients infected with the COVID-19 virus,” he emphasized.
링크 : http://www.bosa.co.kr/news/articleView.html?idxno=2163270
